To further investigate whether ANXA2P2 can affect the efficacy of current liver cancer-targeted drugs, the si-ANXA2P2 group and the negative control were treated with sorafenib (4 μmol/L, 8 μmol/L), regorafenib (5 μmol/L, 10 μmol/L), and lenvatinib (10 μmol/L, 20 μmol/L), respectively, for three days, as described in Methods. This evidence concerns the gene ANXA2P2 and liver cancer.